Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.44 |
| ▸ | PIM1 | P11309 | 7/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | NEK4 | P51957 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12975573 | 1.00 | GSK3B (0.46) | GSK3BPIK3CAPIK3CGNPC1RAB9A | |
| SCHEMBL2882799 | 0.84 | GSK3B (0.52) | GSK3BPIK3CAPIK3CGNPC1RAB9A | |
| SCHEMBL2884697 | 0.79 | HDAC1 (0.33) | NPC1RAB9APTGS2 | |
| SCHEMBL2883153 | 0.78 | GSK3B (0.54) | GSK3BPIK3CAPIK3CGNPC1RAB9A | |
| SCHEMBL12975554 | 0.78 | GSK3B (0.54) | GSK3BPIK3CAPIK3CGNPC1RAB9A | |
| SCHEMBL2883076 | 0.72 | CYP4F2 (0.35) | GPR119 | |
| SCHEMBL2880303 | 0.71 | PIM1 (0.46) | GSK3BGPR119AKR1B1PIM1PIM2 | |
| SCHEMBL6255939 | 0.70 | BCHE (0.46) | GPR119 | |
| SCHEMBL2397448 | 0.68 | GPR119 (0.53) | GSK3BPIK3CAPIK3CGNPC1RAB9A | |
| SCHEMBL2883155 | 0.67 | GPR119 (0.39) | GSK3BNPC1RAB9AGPR119AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | claimed |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | MERCK SERONO SA (CH) | 2009-02-12 | — | — | US | claimed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | claimed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | claimed |
| EP-1549644-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2005-07-06 | — | — | EP | claimed |
| EP-1531813-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | Applied Research Systems ARS Holding N.V. (AN) | 2005-05-25 | — | — | EP | claimed |
| WO-2004007491-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-01-22 | — | — | WO | claimed |
| WO-2004006916-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2004-01-22 | — | — | WO | claimed |
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | LABORATOIRES SERONO S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2008-12-11 | — | — | US | disclosed |
| EP-1931424-A2 | P13K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007030360-A2 | P13K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | disclosed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | disclosed |
| EP-1549644-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2005-07-06 | — | — | EP | disclosed |
| EP-1531813-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | Applied Research Systems ARS Holding N.V. (AN) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004007491-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006916-A1 | USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | ZAP70, BRCA1, ZYX | GSK3B 2843/4885PIK3CA 619/4885PIK3CG 1265/4885 |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | PDPK1, PRKD3, PRKD1 | GSK3B 100/4885PIK3CA 17/4885PIK3CG 52/4885 |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | CATSPER1, PI4KB, MAN2B2 | GSK3B 1040/4885PIK3CA 130/4885PIK3CG 110/4885 |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | PDPK1, PIK3R4, MAP3K3 | GSK3B 126/4885PIK3CA 29/4885PIK3CG 52/4885 |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | BRCA1, ZAP70, F13B | GSK3B 3188/4885PIK3CA 559/4885PIK3CG 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.